🇺🇸 Glecaprevir-pibrentasvir in United States

405 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 66 reports (16.3%)
  2. Drug Interaction — 49 reports (12.1%)
  3. Nausea — 45 reports (11.11%)
  4. Headache — 40 reports (9.88%)
  5. Hepatocellular Carcinoma — 40 reports (9.88%)
  6. Fatigue — 37 reports (9.14%)
  7. Vomiting — 35 reports (8.64%)
  8. Pruritus — 33 reports (8.15%)
  9. Hepatitis C — 31 reports (7.65%)
  10. Malaise — 29 reports (7.16%)

Source database →

Glecaprevir-pibrentasvir in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Glecaprevir-pibrentasvir approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Glecaprevir-pibrentasvir in United States?

Id Care is the originator. The local marketing authorisation holder may differ — check the official source linked above.